Rotigotine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Rotigotine
- Rotigotine: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder
Rotigotine: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Rotigotine is a dopamine agonist originally used to treat Parkinson disease and restless legs syndrome. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), but there are currently 0 clinical trials and only 3 publications (reviews and mechanistic studies) behind this prediction, so it remains a hypothesis-level finding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Restless legs syndrome, Parkinson disease (the US license record contains no approved indication text) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.997% |
| Evidence Level | L4 |
| US Market Status | Cancelled only (the single NDA is cancelled) |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on the literature retrieved, rotigotine is a dopamine agonist that acts on D1 to D5 receptors, with notable activity at D3, D2 and D1. It also shows some activity at 5-HT1A and alpha-2B adrenergic receptors.
ADHD involves dysregulation of dopamine and noradrenaline signalling. The retrieved literature discusses heteromerization between the dopamine D4 receptor and the α2A adrenoceptor, both of which have been genetically linked to ADHD. In addition, restless legs syndrome (one of rotigotine’s original indications) frequently co-occurs with ADHD, and the two conditions share dopaminergic involvement.
This is indirect, hypothesis-level support. No ADHD-specific rotigotine data are available, so the link remains a research question rather than an established finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18656214 | 2008 | Review | Revue neurologique | Overview of restless legs syndrome, a sensorimotor disorder affecting 2–3% of people in Western countries |
| 21476956 | 2011 | Review | Current pharmaceutical design | Review of pharmacological options for restless legs syndrome in children |
| 34182128 | 2021 | Preclinical/Mechanistic | Pharmacological research | Heteromerization of α2A adrenoceptors with dopamine D4 receptor variants; relevant to ADHD and impulse-control disorders |
None of these publications tests rotigotine in ADHD.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021829 (cancelled) | Neupro (UCB, Inc.) | Patch, extended release | Not stated in the license record |
Safety Considerations
- Disease-level contraindication signals (knowledge graph, not label text): hypertensive disorder, hypertension, multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, drug-induced dyskinesia.
- Drug Interactions: 51 interactions were identified, and the 20 listed are all rated Moderate. They include:
- Opioids and related drugs: morphine (including liposomal), codeine, opium, difenoxin, diphenoxylate
- Cannabinoids: dronabinol, nabilone
- Sedating antihistamines: promethazine, chlorpheniramine, cetirizine, brompheniramine, carbinoxamine, clemastine, azelastine (nasal)
- Others: metoclopramide, sibutramine, ethanol, dextromethorphan, ioflupane I-123
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high (99.997%), but there are no clinical trials and the literature is indirect: two restless legs reviews and one receptor-level preclinical study. The evidence level is L4, with no rotigotine-specific ADHD data. Moreover, the only US NDA is cancelled.
To proceed, the following is needed:
- Rotigotine-specific preclinical or clinical data in ADHD
- Detailed mechanism of action data, especially for D4 and α2 receptor activity
- FDA package insert warnings and contraindications
- Review of the knowledge-graph contraindication signals (hypertension, orthostatic hypotension) and the moderate drug interactions, particularly for a paediatric ADHD population
- Clarification of the regulatory and formulation situation, given the cancelled US license
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.